{"id":"NCT01438060","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-08","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2011-09-21","resultsPosted":"2012-03-05","lastUpdate":"2013-12-02"},"enrollment":232,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dementia, Alzheimer Type"],"interventions":[{"type":"DRUG","name":"Aripiprazole (BMS-337039)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aripiprazole (BMS-337039)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.","primaryOutcome":{"measure":"Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase","timeFrame":"Baseline (Day 0), Week 10","effectByArm":[{"arm":"Placebo","deltaMin":12.12,"sd":0.6},{"arm":"Aripiprazole","deltaMin":12.29,"sd":0.59}],"pValues":[{"comp":"OG000 vs OG001","p":"0.802"},{"comp":"OG000 vs OG001","p":"0.169"}]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":105},"commonTop":["URINARY TRACT INFECTION","SOMNOLENCE","BRONCHITIS","FALL","INSOMNIA"]}}